Episode Details
Back to Episodes
Humana's Stock Surge: Pros & Cons
Description
Humanas stock, HUM, has surged 13.2% in the past six months, outperforming the S&P 500. The company, which derives most of its revenue from federal contracts, specializes in Medicare Advantage plans. While revenue has grown steadily at 11.9% annually, earnings per share have dipped by 5.5% in the same period. Despite its scale and momentum, investors should consider the efficiency of growth before investing, as HUM trades at 26 times forward price-to-earnings.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/16b15f76449a7404